Many investors view the healthcare sector as a safe haven when the stock market is turbulent. Here are three no-brainer ...
Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) treatment has been approved by the Medicines and Healthcare ...
Vertex announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted approval for ALYFTREK, a once-daily ...
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Alyftrek (triple combination medicine ...
UK MHRA approves Vertex’s Alyftrek, a once-daily next-in-class CFTR modulator to treat cystic fibrosis: London Monday, March 10, 2025, 10:00 Hrs [IST] Vertex Pharmaceuticals, a ...
Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...
However, Vertex remains an attractive stock. Since that setback, the biotech has earned approval for Alyftrek, a next-generation medicine in its core area of expertise, cystic fibrosis (CF).
Growth is expected from U.S. launches of ALYFTREK and JOURNAVX, along with the continued ramp of CASGEVY globally. JOURNAVX is anticipated to contribute more significantly in the second half of ...
The agency approved it based on two Phase III studies showing the drug to be as effective as another combination therapy at improving lung function.
Zacks Investment Research on MSN3d
Company News for Mar 11, 2025
Shares of Vertex Pharmaceuticals Incorporated VRTX rose 2.4% on its cystic fibrosis drug Alyftrek getting approval in the United Kingdom. Shares of Tesla, Inc. TSLA plummeted 15.4% on the broad-based ...
We appreciate that Vertex is using its healthy cash flows from its CF franchise to expand its portfolio, and is focused on delivering strong commercial launches of Alyftrek and Journavx.